Search Results
Your search for ,her matches 3340 pages
Showing 401 - 450Antibacterial Treatment May Resolve Acute Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Researchers have found that acute radiation dermatitis may involve the skin bacterium Staphylococcus aureus and that a simple, low-cost treatment may prevent severe cases in patients undergoing radiation therapy, according to two novel studies published by Kost et al—one a randomized clinical trial ...
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 trial presented at the 2023 American Association for Cancer...
Newly Identified Risk Factors May Point to a Heightened Risk for Early-Onset Colorectal Cancer Among Younger Adult Patients
Researchers have identified four warning signs and symptoms that may indicate an elevated risk of early-onset colorectal cancer, according to a new study published by Fritz et al in the Journal of the National Cancer Institute. The findings may be key to helping physicians more effectively detect...
Expert Point of View: Kathleen Moore, MD, MS
“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
Christina M. Dieli-Conwright, PhD, MPH, on Resistance Exercise as Medicine: Improving Health and Cancer Outcomes
Christina M. Dieli-Conwright, PhD, MPH, of Dana-Farber Cancer Institute, discusses her research on the ways in which postdiagnosis exercise, particularly resistance exercise, can build strength and muscle mass and affect cancer outcomes. She also describes her focus on biomarkers related to body...
I’m BRCA-Positive and Survived Both Breast and Pancreatic Cancers
Cancer has stalked my family for generations. My mother, brother, and maternal uncle were diagnosed with melanoma. Fortunately, all survived. When my sister was diagnosed with early-stage invasive ductal carcinoma in 2010, she underwent genetic testing, which showed she was positive for the BRCA2...
ASCO Member Testifies Before Congress, Urging Significant Increase in Federal Cancer Research Funding
Brian Persing, MD, a medical oncologist and hematologist in Mobile, Alabama, and a member of ASCO, the world’s leading professional organization representing nearly 45,000 oncology professionals, testified before the House Appropriations Subcommittee on Labor Health and Human Services and...
Olaparib Plus Ceralasertib May Benefit Pediatric Patients With Cancer Who Have DNA Replication and/or Damage Repair–Deficient Tumors
Researchers have found that a combination of the PARP inhibitor olaparib and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication and/or damage repair deficiencies, according to new findings presented by Gatz et al ...
Diana Azzam, PhD, on Pediatric Cancers: Efficacy of a Precision Medicine Approach
Diana Azzam, PhD, of Florida International University, Robert Stempel College of Public Health and Social Work, discusses her study results, which showed that treatment protocols guided by functional precision medicine yielded significantly longer progression-free survival and improved overall...
USPSTF Announces New Leadership
The U.S. Preventive Services Task Force (USPSTF) recently announced the appointments of Michael J. Barry, MD, as Chair, and Michael Silverstein, MD, MPH, as Vice Chair. Wanda K. Nicholson, MD, MPH, MBA, will remain in her role as Vice Chair. Dr. Barry will assume the role of Chair from Carol M....
City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System
City of Hope in Duarte, California, recently announced that its subsidiary, Cancer Treatment Centers of America (CTCA), will fully transition its clinical locations to City of Hope’s brand. CTCA locations in different cities will now be called City of Hope Atlanta, City of Hope Chicago, and City of ...
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Elizabeth M. Jaffee, MD, FAACR, to Receive 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) will honor Elizabeth M. Jaffee, MD, FAACR, AACR Past President, with the 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the 2023 AACR Annual Meeting, to be held on April 14–19 in Orlando,...
Nobel Laureate Carolyn R. Bertozzi, PhD, to Receive 2023 AACR Award for Outstanding Achievement Cancer Research
The American Association for Cancer Research (AACR) will honor Nobel Laureate Carolyn R. Bertozzi, PhD, with the 2023 AACR Award for Outstanding Achievement in Chemistry in Cancer Research during the 2023 AACR Annual Meeting on April 14–19 in Orlando, Florida. Dr. Bertozzi’s award lecture will be...
Yes, You Should Attend the 2023 ASCO Annual Meeting
The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent? Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings,...
Kerin Adelson, MD, Named MD Anderson Chief Quality and Value Officer
The University of Texas MD Anderson Cancer Center has announced the appointment of Kerin Adelson, MD, as the institution’s Chief Quality and Value Officer. An accomplished clinician and researcher with extensive leadership experience in cancer care, Dr. Adelson will also hold a faculty appointment...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery at the Medical College of Wisconsin, highlighted the significance of the 80% response rates to neoadjuvant immunotherapy in primary...
Two Cancer Experts to Head New Tisch Cancer Hospital at Mount Sinai Hospital
Two cancer experts have been named to lead Mount Sinai’s new Tisch Cancer Hospital, which is under development and expected to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been...
The Will to Go On
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Jamie Takayesu, MD, on Genitourinary Cancer: Disparity in Physicians’ Assessment of Sexual Dysfunction in Women vs Men
Jamie Takayesu, MD, of the University of Michigan, discusses her findings on how frequently physicians are asking their female and male patients with genitourinary cancers about sexual dysfunction. Although 62.79% of women with genitourinary cancer who received brachytherapy thought they should be ...
Early Exposure to Health-Care Inequities Sets the Stage for a Leadership Role in Global Oncology for Satish Gopal, MD, MPH
In this installment of The ASCO Post’s Global Oncology series, guest editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Satish Gopal, MD, MPH, Director of the Center for Global Health at the National Cancer Institute (NCI). In this role, he oversees the development of initiatives and...
Three MD Anderson Researchers Elected AAAS Fellows
Three researchers at The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS) for their notable contributions to the field of cancer research. This distinction is one of the highest honors in the scientific research...
A Pioneering Oncologist, a Pilot, and a Choral Singer, Among Other Things
“There is and always has been, more to me than medicine. Ever since the university, I have loved flying. Ever since school, I have adored choral singing,” writes John F. Smyth, MD, in his memoir Taming the Beast: Memoirs of a Pioneering Cancer Physician. Dr. Smyth is Emeritus Professor of Medical...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Patricia M. LoRusso, DO, PhD (hc), Elected 2023–2024 AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the AACR Annual Meeting...
BRAF V600E–Mutated Colon Cancer
This is Part 2 of The Evolving Targeted Treatment Landscape for Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. John Strickler, Stacey A. Cohen, and Harshabad Singh discuss the management of BRAF...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
Vanessa B. Sheppard, PhD, Named American Cancer Society Researcher of the Year
In recognition of her cancer research, Vanessa B. Sheppard, PhD, Associate Director for Community Outreach and Engagement and Health Disparities Research at Massey Cancer Center, has received the 2022 Researcher of the Year Award from the American Cancer Society (ACS). Dr. Sheppard, who was awarded ...
Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer
Steffi Oesterreich, PhD, and Adrian V. Lee, PhD, breast cancer researchers at UMPC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, MD, PhD, Professor of Radiology at UMPC Magee-Womens Hospital, all of the University of Pittsburgh School of Medicine, have received ...
Expert Point of View: Aparna R. Parikh, MD
Aparna R. Parikh, MD, Assistant Professor of Medicine, Harvard Medical School, and Director of the Massachusetts General Hospital Cancer Center’s Global Cancer Care Program, Boston, shared her thoughts on the C-800 study of balstilimab plus botensilimab with The ASCO Post. Noting that the...
Understanding the Link Between Prognostic Perception and Patient-Oncologist Prognostic Discordance in the Advanced Cancer Setting
Studies have shown that although patients with advanced cancer want their oncologists to give them an honest assessment of their prognosis, most patients still perceive their illness as curable.1 And that lack of understanding of their prognosis can lead to reduced use of hospice care and increased ...
Triplet and Quadruplet Regimens in Smoldering Multiple Myeloma
Combination regimens beyond lenalidomide/dexamethasone were shown to significantly delay—and potentially prevent altogether—progression from smoldering disease to active multiple myeloma, according to researchers who reported findings from two studies at the 2022 American Society of Hematology...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
President Biden Announces Key Appointments to National Cancer Advisory Board
On February 2, 2023, President Joseph Biden announced his intent to appoint six members to the National Cancer Advisory Board (NCAB). The NCAB plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. The NCAB...
First-Line Therapy for Metastatic Malignant Melanoma
This is Part 3 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss the first-line treatment of metastatic melanoma. The patient is a 32-year-old woman...
Expert Point of View: Jane N. Winter, MD and Catherine Bollard, MBChB, MD
Offering their thoughts on the study by Williams et al from the St. Jude Lifetime Cohort were Jane N. Winter, MD, Immediate Past President of the American Society of Hematology (ASH), and Catherine Bollard, MBChB, MD. Both moderated press briefings where the results were presented or discussed....
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Decline in PSA Level After Treatment With Enzalutamide: Effect on Metastasis and Survival
A decline in prostate-specific antigen (PSA) levels following treatment with the androgen receptor inhibitor enzalutamide may effectively predict improved survival rates among patients with nonmetastatic castration-resistant prostate cancer, according to a post hoc analysis of data from the PROSPER ...
Acupuncture for Chemotherapy-Induced Peripheral Neuropathy: Health-Related Quality-of-Life Outcomes From a Randomized Clinical Trial
Guest Editor’s Note: Chemotherapy-induced peripheral neuropathy is a common and potentially debilitating side effect of neurotoxic chemotherapy. It worsens the quality of life for many cancer survivors, with limited treatment options. In this installment of The ASCO Post’s Integrative Oncology...
The Beauty and the Beast of Cancer
The most humbling—and fortunate—experience I’ve had since I was diagnosed with osteosarcoma 13 years ago at the age of 43 was being treated in the pediatric wing of a major cancer center in New York City. It is pretty difficult to feel sorry for yourself when you are sitting next to a 14-year-old...
Raised in Africa, Surgeon Kristin Flowers, MD, Continues the Tradition of Service in a Rural Hospital in Alaska
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kristin Flowers, MD, a general surgeon at Tanana Valley Clinic at Fairbanks Memorial Hospital in rural Alaska. Dr. Flowers’ surgical areas of interest include treating...
MD Anderson’s Guillermina Lozano, PhD, Receives AAMC Award for Distinguished Research in the Biomedical Sciences
In recognition of her work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, PhD, Chair of Genetics at The University of Texas MD Anderson Cancer Center, Houston, has received the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association...
Common Immune-Related Adverse Events: Spotlight on Gastrointestinal and Hepatic Toxicities
At the inaugural MD Anderson Clinical Education Symposium on Immunotherapy Organ Toxicity Management (IOTOX), a panel of experts discussed common immune-related adverse events associated with immune checkpoint inhibitor therapy, including gastrointestinal (GI), hepatic, dermatologic, pulmonary, and ...
Terry Hyslop, PhD, Joins SKCC as Cancer Risk and Control Program Co-Leader and Center for Health Equity Director
Jefferson Health’s Sidney Kimmel Cancer Center (SKCC) recently welcomed transdisciplinary population health researcher Terry Hyslop, PhD, as Co-Leader of the Cancer Risk and Control Program. Dr. Hyslop is returning to SKCC from the Duke Cancer Institute, where she served as Professor of...
New Leaders Named for the University of Arkansas for Medical Sciences
The University of Arkansas for Medical Sciences (UAMS) has named Michelle W. Krause, MD, MPH, Senior Vice Chancellor for UAMS Health and Chief Executive Officer for UAMS Medical Center, and Ahmed Abuabdou, MD, MBA, Chief Clinical Officer for UAMS Medical Center. Dr. Krause and Dr. Abuabdou have...
Expert Point of View: Maryam B. Lustberg, MD, MPH
Maryam B. Lustberg, MD, MPH, Chief of Breast Medical Oncology at Yale Cancer Center, New Haven, shared her thoughts on TROPiCS-02 with The ASCO Post. “The progression-free survival and overall survival results of the phase III TROPiCS-02 trial position sacituzumab govitecan-hziy as an important...
Despite Similar Recurrence Scores, Breast Cancer Outcomes Differ by Race
Suboptimal treatment, which often underlies worse outcomes for cancer in racial minorities, did not explain a recent finding from the landmark RxPONDER study: non-Hispanic Black women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer had worse outcomes compared with...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
